{"id":29130,"date":"2022-04-17T12:32:14","date_gmt":"2022-04-17T10:32:14","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=29130"},"modified":"2022-05-02T10:24:09","modified_gmt":"2022-05-02T08:24:09","slug":"mes-a-prop-de-personalitzar-el-tractament-de-lesclerosi-multiple","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/mes-a-prop-de-personalitzar-el-tractament-de-lesclerosi-multiple\/","title":{"rendered":"M\u00e9s a prop de personalitzar el tractament de l&#8217;esclerosi m\u00faltiple"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Un <a rel=\"noreferrer noopener\" href=\"https:\/\/www.imim.cat\/noticies\/1066\/demostren-la-possible-utilitat-dun-marcador-per-personalitzar-el-tractament-amb-anti-cd20-en-pacients-amb-esclerosi-multiple\" target=\"_blank\">estudi<\/a> del Grup de Recerca en Neuroimmunologia de l&#8217;<a rel=\"noreferrer noopener\" href=\"http:\/\/www.imim.es\/\" target=\"_blank\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques&nbsp;(IMIM)<\/a> ha trobat un <strong>marcador<\/strong> que podria <strong>ajudar a personalitzar i millorar l&#8217;efic\u00e0cia i la seguretat del tractament de l&#8217;esclerosi m\u00faltiple<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;esclerosi m\u00faltiple \u00e9s una <strong>malaltia autoimmune<\/strong> en qu\u00e8 els propis <strong>limf\u00f2cits B<\/strong> <strong><a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/el-consum-dalcohol-durant-lembaras-provoca-canvis-epigenetics-al-fetus\/\" target=\"_blank\">ataquen la mielina<\/a> que recobreix els nervis<\/strong>. En l&#8217;actualitat, es tracta amb <strong>anticossos monoclonals anti-CD20<\/strong> que s&#8217;uneixen a la prote\u00efna CD20 dels limf\u00f2cits B. Aix\u00ed, les c\u00e8l\u00b7lules NK del sistema immunitari eliminen aquests limf\u00f2cits, controlant la malaltia. Aquest tractament <strong>s&#8217;administra cada 6 mesos<\/strong> a tots els pacients tot i que <strong>aquest per\u00edode podria no ser adequat per a tots<\/strong> ells. Per aix\u00f2, tal com diu <strong>Jos\u00e9 Enrique Mart\u00ednez<\/strong>, responsable de l&#8217;estudi, \u00abtrobar un marcador que permeti saber quins pacients necessiten el tractament als 6 mesos i quins pacients poden esperar pot ser molt \u00fatil per personalitzar els tractaments\u00bb.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aix\u00f2 \u00e9s precisament el que han fet en aquest estudi on s&#8217;han analitzat dades de <strong>38 pacients<\/strong> amb esclerosi m\u00faltiple. Els resultats han mostrat que els pacients les <strong>c\u00e8l\u00b7lules NK<\/strong> dels quals expressen <strong>nivells m\u00e9s alts del receptor NKG2C<\/strong> tenen una funci\u00f3 m\u00e9s intensa; \u00e9s a dir, <strong>maten m\u00e9s limf\u00f2cits B i retarden la seva repoblaci\u00f3<\/strong>. Per aix\u00f2 \u201cel receptor NKG2C pot ser un marcador molt interessant, ja que els pacients que en tinguin una major pres\u00e8ncia potser podrien endarrerir la dosi del tractament\u201d, segons diu Mart\u00ednez.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Encara \u00e9s massa aviat per canviar les pautes del tractament, per\u00f2 aquest estudi ha obert la porta per poder tractar l&#8217;esclerosi m\u00faltiple d&#8217;una manera m\u00e9s personalitzada.<\/p>\n\n\n\n<div style=\"height:76px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudi realitzat per l&#8217;IMIM ha descobert un possible marcador que permetria personalitzar el tractament amb anti-CD20 en pacients amb esclerosi m\u00faltiple.<\/p>\n","protected":false},"author":28,"featured_media":29077,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[761,213,411,757],"new-type":[35,43],"class_list":["post-29130","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-biomarcadors","tag-imim","tag-immunologia","tag-tractament","new-type-noticies","new-type-recomanem"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/29130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=29130"}],"version-history":[{"count":7,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/29130\/revisions"}],"predecessor-version":[{"id":29178,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/29130\/revisions\/29178"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/29077"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=29130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=29130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=29130"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=29130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}